Welcome to Awesome Blog Design perfect blog
Business, Healthcare

TROPION-Lung01 head-to-head phase 3 trial initiated to evaluate datopotamab deruxtecan Versus docetaxel in previously treated patients with advanced or metastatic NSCLC without actionable genomic alterations

TOKYO & MUNICH & BASKING RIDGE, N.J. — (BUSINESS WIRE) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung01, a global pivotal phase 3 head-to-head study of datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 directed antibody